Amgad M Moussa1, Etay Ziv2. 1. Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Suite H-112, New York, NY, 10065, USA. 2. Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Suite H-112, New York, NY, 10065, USA. zive@mskcc.org.
Abstract
PURPOSE OF REVIEW: Radiogenomics is a growing field that has garnered immense interest over the past decade, owing to its numerous applications in the field of oncology and its potential value in improving patient outcomes. Current applications have only begun to delve into the potential of radiogenomics, and particularly in interventional oncology, there is room for development and increased value of these applications. RECENT FINDINGS: The field of interventional oncology (IO) has seen valuable radiogenomic applications, from prediction of response to locoregional therapies in hepatocellular carcinoma to identification of genetic mutations in non-small cell lung cancer. Future directions that can increase the value of radiogenomics include applications that address tumor heterogeneity, predict immune responsiveness of tumors, and differentiate between oligoprogression and early widespread progression, among others. Radiogenomics, whether in terms of methodologies or applications, is still in the early stages of development and far from maturation. Future applications, particularly in the field of interventional oncology, will allow realization of its full potential.
PURPOSE OF REVIEW: Radiogenomics is a growing field that has garnered immense interest over the past decade, owing to its numerous applications in the field of oncology and its potential value in improving patient outcomes. Current applications have only begun to delve into the potential of radiogenomics, and particularly in interventional oncology, there is room for development and increased value of these applications. RECENT FINDINGS: The field of interventional oncology (IO) has seen valuable radiogenomic applications, from prediction of response to locoregional therapies in hepatocellular carcinoma to identification of genetic mutations in non-small cell lung cancer. Future directions that can increase the value of radiogenomics include applications that address tumor heterogeneity, predict immune responsiveness of tumors, and differentiate between oligoprogression and early widespread progression, among others. Radiogenomics, whether in terms of methodologies or applications, is still in the early stages of development and far from maturation. Future applications, particularly in the field of interventional oncology, will allow realization of its full potential.
Authors: Xin Chen; Siu Tim Cheung; Samuel So; Sheung Tat Fan; Christopher Barry; John Higgins; Kin-Man Lai; Jiafu Ji; Sandrine Dudoit; Irene O L Ng; Matt Van De Rijn; David Botstein; Patrick O Brown Journal: Mol Biol Cell Date: 2002-06 Impact factor: 4.138
Authors: Gillian C Barnett; Charlotte E Coles; Rebecca M Elliott; Caroline Baynes; Craig Luccarini; Don Conroy; Jennifer S Wilkinson; Jonathan Tyrer; Vivek Misra; Radka Platte; Sarah L Gulliford; Matthew R Sydes; Emma Hall; Søren M Bentzen; David P Dearnaley; Neil G Burnet; Paul D P Pharoah; Alison M Dunning; Catharine M L West Journal: Lancet Oncol Date: 2011-12-12 Impact factor: 41.316
Authors: Sudeep Banerjee; David S Wang; Hyun J Kim; Claude B Sirlin; Michael G Chan; Ronald L Korn; Aaron M Rutman; Surachate Siripongsakun; David Lu; Galym Imanbayev; Michael D Kuo Journal: Hepatology Date: 2015-07-01 Impact factor: 17.425
Authors: Erling A Hoivik; Erlend Hodneland; Julie A Dybvik; Kari S Wagner-Larsen; Kristine E Fasmer; Hege F Berg; Mari K Halle; Ingfrid S Haldorsen; Camilla Krakstad Journal: Commun Biol Date: 2021-12-06